Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Cream in Cutaneous Lichen Planus
NCT03697460Phase 2Completed
- Start
- Aug 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib cream in lichen planus (LP). Primary endpoints: Modified Clinical Assessment Scale of Severity for Index Lesion Signs and Symptoms at 4 weeks and Total Body Lesion Count at 4 weeks. Started Aug 2018; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
lichen planus (LP)
Beyond the preview
Go deeper on NCT03697460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697460.